The Courier Mail | LTR hard sell not required

Following last week’s announcement of positive results from our SPONTAN® pivotal bioequivalence clinical study, LTR Pharma was featured in The Courier Mail’s City Beat by business reporter Glen Norris over the weekend.

Here’s an excerpt:

“LTR, which is developing an intranasal spray treatment called SPONTAN, on Friday released data that is expected to support the fast-tracking of regulatory approval of the product. The stock has more than doubled this month and jumped 40 per cent following the release of the study on Friday morning.”

Click here to read the article.